Literature DB >> 7679725

Cyclothiazide treatment unmasks AMPA excitotoxicity in rat primary hippocampal cultures.

P C May1, P M Robison.   

Abstract

Mechanisms of non-NMDA receptor-mediated excitotoxicity were studied in embryonic rat hippocampal cultures using kainic acid (KA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) as agonists. Under basal culture conditions, overnight treatment with AMPA resulted in negligible excitotoxicity as assessed by phase-contrast microscopy and measurement of lactate dehydrogenase (LDH) release. In contrast, similar treatment with KA resulted in marked excitotoxic morphologic changes and release of LDH. Cotreatment of cultures with AMPA but not NMDA effectively blocked KA toxicity, suggesting that AMPA-induced rapid desensitization of the AMPA/KA receptor could account for the lack of prominent direct toxicity as well as AMPA's ability to block KA toxicity. To test this hypothesis, cultures were briefly pretreated with 10 microM cyclothiazide, a drug reported to block desensitization of the AMPA/KA receptor, and then exposed overnight to cyclothiazide plus AMPA and/or KA. Cyclothiazide-treated cultures were now vulnerable to AMPA as well as KA; moreover, AMPA was unable to block KA toxicity completely, suggesting that cyclothiazide impaired AMPA/KA receptor desensitization. These and related studies suggest that a regulatory site may exist on the AMPA/KA receptor that modulates non-NMDA receptor-mediated excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679725     DOI: 10.1111/j.1471-4159.1993.tb03272.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

Review 1.  AMPA receptor-mediated neurotoxicity: role of Ca2+ and desensitization.

Authors:  Aase Frandsen; Arne Schousboe
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

2.  Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490).

Authors:  D D Schoepp; C R Salhoff; K S Fuson; A I Sacaan; J P Tizzano; P L Ornstein; P C May
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Desensitization of AMPA receptors and AMPA-NMDA receptor interaction: an in vivo cyclic GMP microdialysis study in rat cerebellum.

Authors:  E Fedele; M Raiteri
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices.

Authors:  G Rammes; D Swandulla; G L Collingridge; S Hartmann; C G Parsons
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 5.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

6.  Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons.

Authors:  M S Perkinton; T S Sihra; R J Williams
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

7.  Extracellular acidity potentiates AMPA receptor-mediated cortical neuronal death.

Authors:  J W McDonald; T Bhattacharyya; S L Sensi; D Lobner; H S Ying; L M Canzoniero; D W Choi
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

8.  Cyclothiazide potently inhibits gamma-aminobutyric acid type A receptors in addition to enhancing glutamate responses.

Authors:  Lunbin Deng; Gong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-08       Impact factor: 11.205

9.  Rat cortico-striatal sagittal organotypic slice cultures as ex vivo excitotoxic striatal lesion models.

Authors:  Amy McCaughey-Chapman; Bronwen Connor
Journal:  Heliyon       Date:  2022-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.